BioCentury | Mar 24, 2008
Finance

Nomura's investments

...Specialist healthcare company focused on vascular disease and cancer 2000 $23M series A, 2000 (as Eurogene...
BioCentury | Jul 5, 2004
Finance

Ebb & Flow

Three European companies picked their markets last week and two have hedged their bets by looking to NASDAQ as well as their home markets. Cell cycle company Cyclacel said on Friday that it plans to...
BioCentury | Jul 5, 2004
Clinical News

Orathecin rubitecan regulatory update

SUPG subsidiary EuroGen Pharmaceuticals Ltd. submitted an MAA to the EMEA for Orathecin rubitecan to treat pancreatic cancer in patients who have failed at least one prior chemotherapy regimen. The oral chemotherapy has Orphan Drug...
BioCentury | Jul 1, 2004
Company News

SuperGen submits Orathecin MAA

SUPG subsidiary EuroGen Pharmaceuticals submitted an MAA to the EMEA for Orathecin rubitecan to treat pancreatic cancer in patients who have failed at least one prior chemotherapy regimen. The oral chemotherapy has Orphan Drug designation...
BioCentury | Aug 25, 2003
Finance

Ebb & Flow

...of Merlin's funds. Merlin also was behind the 2001 acquisition of Finland's Oy Quattrogene by Eurogene...
BioCentury | Aug 21, 2003
Financial News

Merlin opens Finland office

...the Nordic region. Merlin was behind the 2001 acquisition of Oy Quattrogene (Kuopio, Finland) by Eurogene...
BioCentury | Jun 16, 2003
Clinical News

Orathecin rubitecan regulatory update

The EMEA granted SUPG's European affiliate, EuroGen Pharmaceuticals Ltd., Orphan Medicinal Product designation for Orathecin to treat pancreatic cancer. The compound is being reviewed by FDA in the U.S. under a rolling NDA submission. SuperGen...
BioCentury | May 12, 2003
Finance

Europe's top decile & quartile

...ValiGen $25.0 Switch $24.5 Biolipox $24.3 Epigenomics $24.1 7TM $23.5 CropDesign $23.4 Ardana BioScience $23.4 Eurogene...
BioCentury | Mar 10, 2003
Clinical News

Decitabine modulator of DNA methylation regulatory update

The EMEA granted SUPG's European affiliate, EuroGen Pharmaceuticals Ltd., Orphan Medicinal Product designation for SUPG's Decitabine to treat myelodysplastic syndrome (MDS). Decitabine is in Phase III trials for MDS. The compound already has Orphan Drug...
BioCentury | Nov 4, 2002
Clinical News

Paclitaxel regulatory update

SUPG's European affiliate EuroGen Pharmaceuticals Ltd. filed a Mutual Recognition Application in the U.K. for European marketing approval of SUPG's generic paclitaxel chemotherapeutic to treat cancer. SuperGen Inc. (SUPG), Dublin, Calif. Product: Paclitaxel Business: Cancer...
Items per page:
1 - 10 of 34
BioCentury | Mar 24, 2008
Finance

Nomura's investments

...Specialist healthcare company focused on vascular disease and cancer 2000 $23M series A, 2000 (as Eurogene...
BioCentury | Jul 5, 2004
Finance

Ebb & Flow

Three European companies picked their markets last week and two have hedged their bets by looking to NASDAQ as well as their home markets. Cell cycle company Cyclacel said on Friday that it plans to...
BioCentury | Jul 5, 2004
Clinical News

Orathecin rubitecan regulatory update

SUPG subsidiary EuroGen Pharmaceuticals Ltd. submitted an MAA to the EMEA for Orathecin rubitecan to treat pancreatic cancer in patients who have failed at least one prior chemotherapy regimen. The oral chemotherapy has Orphan Drug...
BioCentury | Jul 1, 2004
Company News

SuperGen submits Orathecin MAA

SUPG subsidiary EuroGen Pharmaceuticals submitted an MAA to the EMEA for Orathecin rubitecan to treat pancreatic cancer in patients who have failed at least one prior chemotherapy regimen. The oral chemotherapy has Orphan Drug designation...
BioCentury | Aug 25, 2003
Finance

Ebb & Flow

...of Merlin's funds. Merlin also was behind the 2001 acquisition of Finland's Oy Quattrogene by Eurogene...
BioCentury | Aug 21, 2003
Financial News

Merlin opens Finland office

...the Nordic region. Merlin was behind the 2001 acquisition of Oy Quattrogene (Kuopio, Finland) by Eurogene...
BioCentury | Jun 16, 2003
Clinical News

Orathecin rubitecan regulatory update

The EMEA granted SUPG's European affiliate, EuroGen Pharmaceuticals Ltd., Orphan Medicinal Product designation for Orathecin to treat pancreatic cancer. The compound is being reviewed by FDA in the U.S. under a rolling NDA submission. SuperGen...
BioCentury | May 12, 2003
Finance

Europe's top decile & quartile

...ValiGen $25.0 Switch $24.5 Biolipox $24.3 Epigenomics $24.1 7TM $23.5 CropDesign $23.4 Ardana BioScience $23.4 Eurogene...
BioCentury | Mar 10, 2003
Clinical News

Decitabine modulator of DNA methylation regulatory update

The EMEA granted SUPG's European affiliate, EuroGen Pharmaceuticals Ltd., Orphan Medicinal Product designation for SUPG's Decitabine to treat myelodysplastic syndrome (MDS). Decitabine is in Phase III trials for MDS. The compound already has Orphan Drug...
BioCentury | Nov 4, 2002
Clinical News

Paclitaxel regulatory update

SUPG's European affiliate EuroGen Pharmaceuticals Ltd. filed a Mutual Recognition Application in the U.K. for European marketing approval of SUPG's generic paclitaxel chemotherapeutic to treat cancer. SuperGen Inc. (SUPG), Dublin, Calif. Product: Paclitaxel Business: Cancer...
Items per page:
1 - 10 of 34